Cord blood as a source of haematopoietic stem cells (HSC) has several advantages as it is easily available, involves non-invasive collection procedure and is better tolerated across the HLA barrier. Since the first cord blood transplant in 1988, over 1000 cord blood HSC transplants have been done world wide. The present study was carried out for collection, separation, enumeration and cryopreservation of cord blood HSC. 30 samples of cord blood HSC were collected after delivery of infant prior to expulsion of placenta. The average cord blood volume collected was 101.33ml. Mononuclear cell count ranged from 7.36 to 25.6 X 10 7 ml. Viability count of mononuclear cells was 98.4%. After 6 months of cryopreservation, the viability count on revival was over 82.1%.
Introduction

H
aematopoietic Stem Cell (HSC) transplantation has come of age. Over the last four decades, this therapy has been used to correct a variety of bone marrow failure states, inborn errors of metabolism, congenital immunodeficiency states, haematologic malignancies and even solid tumours [1] . This mode of therapy generally involves the ablation of the patient's bone marrow by chemotherapy and/or irradiation and its replacement by pluripotent HSC from a voluntary donor. The major limitation of using HLA matched related sibling donors in HSC transplantation has been that only 30% to 40% of potential recipients in need of such therapy have a HLA matched related family donor [2] . Hence, the search for an alternate source of HSC has led to the development of HSC transplantation (HSCT) protocols from tissues like foetal liver, umbilical cord and mobilised peripheral blood [1] . The first cord blood transplant was performed on a child with Fanconi's anaemia in 1998 [2] . Since then over 1000 cord blood haematopoietic stem cell transplants have been done worldwide [1] . Cord blood as a source of haematopoietic stem cells has several advantages as it is easily available, involves non-invasive collection procedure and is better tolerated across the HLA barrier with lower frequency of Cytomegalovirus infection [1] .
The present study was carried out with a view to establish a HSC Bank in the department of Transfusion Medicine, Armed Forces Medical College, Pune. The aims were firstly, to develop techniques for collection of cord blood maximising the blood volume without compromising on the sterility and quality of stem cell were evaluated in BHI broth before and after cryopreservation to assess the sterility during collection and processing of samples. Removal of red blood cells was done by hydroxy ethyl starch (HES) sedimentation. Mononuclear cell (MNC) counts were done by using Turk's solution in Neubauer chamber. Viability count of MNC was done using Trypan blue dye exclusion test. UCB mononuclear cells were cryopreserved using the cryoprotectant dimethyl sulphoxide (DMSO) at a final concentration of 10%. The HSC in blood bags were stored at -85°C [6, 7, 8] . Aliquot samples were taken for ABO and Rh grouping, sterility testing and revival studies.
Results
30 samples of UCB were collected and cryopreserved. Information regarding the antenatal history, delivery, newborn, placental weight and any complications were noted ( Table 1) . 2 samples were HBsAg positive on testing and were discarded. 2 samples were found to be contaminated by bacteria (aerobic spore bearers) and were discarded. Contaminated samples were collected after vaginal deliveries of women reporting rupture of the membrane 24 hours before delivery. No contamination was observed on culture in the post cryopreservation samples on revival after thawing. The average volume of blood collected was 101.33 ml with a range of 65 to 140 ml (Table 2 and Fig. 1 ). The volume of cord blood collected was analyzed for correlation with the haemoglobin of mother, birth weight of child, sex of the child and placental weight (Table 1 and Fig. 2 ). The coefficient of correlation in this was -0.1, 0.1782, 0.12 and 0.16 respectively, showing thereby that these parameters do not effect the volume of blood collected. The effect of volume of cord blood collected on nucleated cell count was analysed using single tailed paired 't' test. The 't' was 1.373 and was found to be statistically significant; p < 0.10.
The average nucleated cell count/ml of cord blood was 13.97 x 10 7 with a range of 4.8 to 27.2 x 10 7 and an average viability count of 98.4% prior to preservation of the sample ( Table 2 ). One ml of each sample was revived after a variable period of time but within 6 months of preserving the sample. The average nucleated cell count/ml of the revived sample was 0.7116 x 10 7 (i.e 71.16%) with a range of 58% to 80% and average viability count of 82.1% (Table 3 and 4) . This indicated an average loss of 28.84% of progenitor cells. The cell recovery after cryopreservation was evaluated for any effect by the number of days of freezing. The correlation co-efficient in this study was found to be -0.24817, thereby implying a very insignificant negative correlation. Similarly, the effect on cell viability showed a negative correlation co-efficient of 0.13948.
Discussion
Allogenic HSC transplantation derived either from bone marrow or UCB has been successfully used in the treatment of thousands of patients with high risk haematological disorders. The principal limitations of allogenic HSC transplantation are the lack of suitable HLA matched donors and complication of graft versus host disease. Although there are currently more than 1.5 million HLA -A, B and DR typed marrow donors registered in marrow donor registries worldwide, 50% of all patients requiring transplant therapy are still unable to find a suitably matched donor [9] . To alleviate a shortage of suitable donors and reduce the length of the bone marrow donor search process, Rubinstein et al (New York), Bertolini et al (Milano) and Wernet et al (Dusseldorf) initiated Placental Blood Banking Programs almost simultaneously in 1993 [10] .
Approximately 10,000 HLA-A,B, and DR typed UCB HSC have been collected, tested and cryopreserved for clinical use in transplantation worldwide. The present study was carried out to establish a HSC Bank in the Dept of Transfusion Medicine, Armed Forces Medical College, Pune. This study was prompted by the demonstration that UCB can be used as a source of HSC for allogenic transplantation. UCB is abundantly available and easy to collect, and frozen cord blood is immediately available for transplantation. When establishing large cord blood banks, it seems possible to balance common and uncommon HLA types, thus including minorities who are poorly represented within registries of bone marrow donors in adults. Thus, UCB is a novel and unique source of transplantable stem cells that can be used for treatment of diseases that normally require bone marrow transplantation. UCB, which is normally discarded, can be readily collected without danger to the mother or infant and the technical feasibility of using umbilical cord blood for transplantation has been established. UCB from a single birth contains a number of stem cells within the range required for autologous and HLA-compatible allogenic transplantation in both infants and adults and provides comparable number of stem cells to that found in bone marrow. A number of different procedures have been proposed for UCB collections, including open systems in which cord blood is collected by gravity in bottles or plastic bottles, or closed systems in which modified blood collections are used. Data collected in the present study indicate that the closed system allows an average collection of 101.33 ml of cord blood (Median range 99 ml) [11] .
As our experiments have demonstrated, collection of increased volumes of cord blood results in increased number of recovered cells, the ability to routinely harvest large amounts of cord blood should result in more cells available for use in transplantation. To make the banking of cord blood possible on a large scale,it would be preferable to store separated cord blood samples rather than large blood bags. It was demonstrated that optimum number of mononuclear cells could be routinely obtained by HES sedimentation [11] .
In the present study, the haemoglobin of the mother, birth weight of child, sex of child and placental weight did not affect the volume of cord blood sample collected or the nucleated cell counts of the sample which compares well with other studies. Increased volume of cord blood sample resulted in increased recovery of nucleated cell counts, an important surrogate marker of HSC and in turn of the transplant potential of the cord blood sample [11, 4] .
It appeared that cell losses did not occur in frozen samples but were due to variables in the freezing and thawing procedures that were not under direct control. However, it should be noted that it was routinely possible to obtain cell recoveries of more than 82% viability and cell recoveries of 71.16% on an average, which though slightly lower than those in the previous studies, were comparable [1] .
Since the first cord blood transplant performed in 1988 [1] , cord blood transplantation is increasingly used as source of HSC. The number of cord blood transplants reported to Eurocord Registry is 500. More than 500 patients have received cord blood transplants via the New York Cord Blood Bank [1] .
Placental-UCB is now considered to be a useful source of HSC for transplantation. Multiple reports clearly document that donor-derived multilineage haematopoiesis after UCB transplantation is sustained with the longest follow-up of nearly 10 years. With this new source of HSC, we may be able to identify a donor for any given patient who needs a transplant. However, carefully planned and controlled long term studies are still needed for donor selection strategies, collection procedures, processing and banking methodologies
